LYTIR

Company · AGIO

Agios Pharmaceuticals, Inc.

Name as listed on its exchange; filed with the SEC as AGIOS PHARMACEUTICALS, INC.

Nasdaq's symbol directory lists AGIO on Nasdaq as “Agios Pharmaceuticals, Inc. - Common Stock”.

In the 12 months to Nov 8, 2026: insiders sold on 5 occasions ($1.4M); 3 planned-sale notices; 2 filings by holders of 5% or more; 3 congressional trade disclosures; 1 company report (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $1.4M in total.Jul: Insider sales $151KAug: Insider sales $914KOct: Insider sales $371KDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $0Insider sales below: $1.4M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Sarah Gheuens, Chief Medical Officer sold on 5 days all under a 10b5-1 plan latest Oct 26, 2026 sold $1.4M
Every trade (5)
  1. SELLSarah Gheuens, Chief Medical Officer sold Oct 26, 2026 7,866 shares 10b5-1 plan (scheduled) filing $296K
  2. SELLSarah Gheuens, Chief Medical Officer sold Oct 22, 2026 500 shares 10b5-1 plan (scheduled) filing $19K
  3. SELLSarah Gheuens, Chief Medical Officer sold Oct 21, 2026 1,489 shares 10b5-1 plan (scheduled) filing $56K
  4. SELLSarah Gheuens, Chief Medical Officer sold Aug 4, 2026 30,000 shares 10b5-1 plan (scheduled) filing $914K
  5. SELLSarah Gheuens, Chief Medical Officer sold Jul 1, 2026 4,007 shares 10b5-1 plan (scheduled) filing $151K

Planned sales · SEC Form 144

Notice given

A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice

  1. SARAH GHEUENS filed Oct 26, 2026 Officer 7,866 shares planned sale date 10/26/2026 filing $296K
  2. SARAH GHEUENS filed Oct 22, 2026 Officer 500 shares planned sale date 10/22/2026 filing $19K
  3. SARAH GHEUENS filed Oct 21, 2026 Officer 1,489 shares planned sale date 10/21/2026 filing $56K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. Farallon Capital Management, L.L.C. filed Aug 3, 2026 Schedule 13G/A passive filing 9.9%
  2. D. E. SHAW & CO, L.P. filed Jul 2, 2026 Schedule 13G passive filing 5.1%

Congress · STOCK Act

The Althing

Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.

  1. Gilbert Cisneros (D-CA31): Purchase Aug 20, 2026 reported Sep 10, 2026 one of 58 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000
  2. Gilbert Cisneros (D-CA31): Purchase Mar 3, 2026 reported Apr 7, 2026 one of 141 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000
  3. Gilbert Cisneros (D-CA31): Purchase Dec 11, 2025 reported Jan 12, 2026 one of 121 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Results of operations and financial condition filing Nov 5, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.